Sun Pharma to Acquire Organon in Transformational $11.75bn Deal

Sun Pharmaceutical Industries and Organon & Co. have announced a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon in an all-cash transaction valued at approximately $11.75 billion.

The acquisition marks a significant strategic step for Sun Pharma, substantially expanding its global footprint and diversifying its portfolio beyond generics into higher-value segments. Organon brings a broad portfolio of more than 70 products spanning women’s health, biosimilars and established medicines, with a commercial presence across over 140 markets.

The deal is expected to position Sun Pharma among the leading global players in women’s health and strengthen its presence in regulated markets, particularly the United States. It also aligns with the company’s strategy to grow its innovative and specialty business alongside its core generics operations.

Sun Pharma highlighted anticipated synergies from combining complementary portfolios and leveraging Organon’s established brands and infrastructure. The transaction is also expected to enhance scale, with the combined entity projected to generate over $12 billion in annual revenues.

Both companies’ boards have approved the agreement, which remains subject to regulatory and shareholder approvals. Completion is anticipated in early 2027.

The acquisition represents one of the largest outbound deals by an Indian pharmaceutical company and underscores ongoing consolidation trends within the global pharma sector, as companies seek to expand capabilities and access new growth opportunities.